CTKB Stock — Cytek Biosciences Inc

Cytek Biosciences Inc (CTKB)

Updated October 16, 2026.

CTKB is a Stock. Total return is -72.0% over the past 5.2 years, 158.1 points behind SPY at 86.1%.

Cytek Biosciences develops and sells cell analysis instruments and reagents used in biomedical research and clinical diagnostics, including flow cytometry systems sold under the Cytek, Amnis, and Guava brand names to pharmaceutical companies, academic institutions, and contract research organizations globally. The company does not currently have an established distribution program. This stock appeals to investors interested in life sciences instrumentation and research tools rather than those seeking current income.

CTKB performance versus SPY

Price and return data through 2026-10-16.

Total return is -72.0% over the past 5.2 years, 158.1 points behind SPY at 86.1%. Over the past year its total return — price change plus distributions reinvested — is 30.6%. Its deepest 1-year drawdown was 42.9%.

CTKB key facts

Asset type

Stock

Asset class

Equity

Inception date

07/23/2021

Distribution frequency

None

Last close

$5.25 (as of 2026-10-16)

Market cap

$682,412,078

Average volume

1045418.0

Beta

1.186

Payout ratio

0.0%

Forward P/E

370.3704

EPS

$-0.63

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CTKB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 42.9%.

Who may consider CTKB — and who may not

It is a weaker fit for investors who need monthly cash flow (CTKB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CTKB

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions